I use Omnipod 5: what the 2026 recall and pod correction mean
FDA posted two separate 2026 Omnipod safety actions. Here is how to check affected Pods, spot possible insulin under-delivery, and know when high blood sugar may be an emergency.
Author: Brian “Weence” Bateman
Brian “Weence” Bateman is a health and medical writer who covers public health updates, healthcare policy, and medical developments affecting communities across the United States. He works closely with dentists and healthcare providers and focuses on making complex medical information clear, accurate, and useful for everyday readers.
-
-
When should parents ask about an early MMR dose during the U.S. measles surge?
CDC’s May 29, 2026 update says 1,983 confirmed U.S. measles cases had been reported as of May 28. Here is when parents should ask about an early MMR dose, what it changes, and what it does not. ([cdc.gov](https://www.cdc.gov/measles/data-research/index.html))
-
At what Air Quality Index should someone with asthma stay inside?
For many people with asthma, AQI above 100 is the point to start changing outdoor plans. Here is how to use each air-quality range, when to move activities indoors, and when symptoms mean it is time to get help.
-
Should you ask for an apoB test with your cholesterol check?
ApoB is getting new attention after a 2026 JAMA analysis and updated cholesterol guidance. Here is what the test measures, who may want to ask about it, and why most people do not need to rush to add it automatically.
-
Do I Need to Stop Using Recalled MG217 Eczema Cream?
FDA says one lot of MG217 eczema cream was recalled after Staphylococcus aureus contamination was found. Here is how to check your tube, why eczema patients may face higher risk, and what symptoms should prompt medical care.
-
Who Qualifies for Medicare’s $50 GLP-1 Bridge Starting July 1, 2026?
CMS’s new Medicare GLP-1 Bridge starts July 1, 2026, but it is not broad new obesity-drug coverage for everyone. Here is who may qualify, which drugs and uses are included, and what the $50 monthly price does not count toward under Part D.
-
Dexcom G7 stolen-sensor recall: how to check your lot number and what to do now
FDA posted a Dexcom safety notice on May 29 after the company said two stolen G7 sensor lots entered the U.S. market. Here is how to check your lot number, when backup fingerstick checks matter, and which symptoms need prompt care.
-
Should Americans worry about Andes virus after the cruise ship outbreak?
The Andes virus outbreak linked to the M/V Hondius is serious for exposed travelers, but most Americans do not need testing or major changes unless they had a specific exposure or hear from public health officials.
-
New U.S. Cholesterol Guidance Highlights Earlier Risk Review
A March 2026 multisociety guideline says some adults may need earlier cholesterol risk review, one-time Lp(a) testing, and more personalized prevention decisions.
-
Cruise Ship Andes Virus Outbreak: How Worried Should People in the U.S. Be?
CDC says the risk to the general U.S. public is low, but cruise passengers, traced contacts, and anyone with a known close exposure should watch for symptoms and act quickly if they get sick.
-
Can You Self-Collect an HPV Test for Screening Now? What Changed in 2026
ACOG now includes patient-collected high-risk HPV screening in cervical cancer guidance for average-risk adults ages 30 to 65, but the change is narrower than many headlines suggest. Federal preventive-coverage changes tied to the HRSA update generally begin with plan years starting in 2027, and a positive result still usually leads to in-person follow-up.
-
Why the FDA’s trial-results push matters for patients and readers
The FDA is pressing more than 2,200 sponsors and researchers to post required clinical trial results to ClinicalTrials.gov. For patients and readers, the issue is simple: missing results can distort what we think works, what does not, and how safe a medical product really is.
-
Long COVID fatigue study raises interest in fluvoxamine, not a new standard
A new randomized trial found a signal that fluvoxamine may ease long COVID fatigue, but the evidence is still early and does not change routine care yet. CDC guidance says there are no approved tests or treatments for Long COVID, and treatment remains focused on symptoms and support.
-
Postpartum diabetes testing after gestational diabetes: what the trial found
A randomized trial suggests that moving the postpartum glucose test to the hospital stay may help more people with gestational diabetes complete screening. The result points to a practical problem: after delivery, follow-up testing can fail because of logistics, not just motivation.
-
Can fluvoxamine help long COVID fatigue? Early trial results show a possible signal, but it is not practice-changing
A new randomized study suggests fluvoxamine may ease long COVID fatigue for some people, but the finding is narrow, early, and not enough to change routine care. CDC guidance still says long COVID is diagnosed clinically, there is no approved test, and treatment is focused on symptom management while research continues.
-
FDA’s March 2026 rare-disease approvals: what families should know
Three FDA decisions in March 2026 gave families in the rare-disease world something unusual: approved options for conditions that previously had few or none. Here’s what changed, what the evidence looked like, and what still needs to be watched closely.
-
RSV vaccine in pregnancy: what parents of newborns should know
There are two main ways to help protect babies from severe RSV: maternal vaccination during a narrow pregnancy window, or an infant RSV monoclonal antibody after birth. CDC says the right option depends on timing, eligibility, and whether a mother already received RSV vaccine in a previous pregnancy.
-
FDA pushes better pregnancy safety data for medicines
The FDA has issued new guidance aimed at improving how pregnancy safety data are collected for drugs and biologics. For patients, the practical takeaway is not that treatment rules changed today, but that the evidence base for medicine use in pregnancy may become more useful over time.
-
CDC’s March 2026 kidney disease update supports earlier screening
New CDC estimates show chronic kidney disease remains common in the U.S. and often goes unnoticed. Adults with diabetes, high blood pressure, heart disease, or a family history of kidney disease may have the most to gain from earlier screening and follow-up in primary care.
-
Breast Screening Debate Heats Up as U.S. Guidance Stands
Breast cancer screening is back in the news because policy leaders and researchers are revisiting how mammograms should be recommended and covered. For most average-risk U.S. women, the practical advice has not changed: keep following current screening guidance and confirm your schedule with your clinician.
-
FDA Pushes Faster Trial Reporting as NIH Updates Its Rules
The FDA is pressing sponsors and researchers to report clinical trial results on time, saying missing data can distort what doctors and patients think they know. A new FDA push and an NIH policy update are raising the stakes for transparency as the clinical-trials system evolves.
-
FDA expands Enhertu use in early HER2-positive breast cancer
The FDA’s May 15 approval adds two early-stage breast cancer uses for Enhertu, also known as fam-trastuzumab deruxtecan-nxki. The update matters for some adults with HER2-positive disease, but it does not change screening guidance or replace a discussion about surgery, chemotherapy, and other treatment options with an oncology team.
End of content
End of content
